Communicable Diseases, Emerging: Clinical Trials

4 trials for Communicable Diseases, Emerging, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 suspended, 1 terminated. 4 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 1, Recruiting 1, Suspended 1, Terminated 1
Phase 32Recruiting 1, Terminated 1

Follow Communicable Diseases, Emerging: new trials by email Literature Review of Communicable Diseases, Emerging trials Research Report on Communicable Diseases, Emerging

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ARN-75039 Lassa Fever Treatment in West Africa
ARN-75039 high, Intravenous ribavirin, ARN-75039 low - Lassa Fever
Phase 2SuspendedArisan Therapeutics, Inc.1352026-02-142026-07-06
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Favipiravir, Ribavirin, Dexamethasone - Lassa Fever
Phase 2 / Phase 3RecruitingIrrua Specialist Teaching Hospital17552025-05-022026-02-04
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Baricitinib, Placebo - COVID-19, Emerging Infectious Disease
Phase 2 / Phase 3TerminatedOslo University Hospital2902021-06-032023-02-06
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Anti-Influenza Immune Plasma, Standard Care - Influenza A, Influenza B
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)982010-12-012017-09-05

Narrower conditions

Hemorrhagic Fevers, Viral (2)  ·  Lassa Fever (2)  ·  COVID-19 (1)  ·  Neglected Diseases (1)  ·  Orthomyxoviridae Infections (1)

Broader conditions

Communicable Diseases (4)  ·  Disease Attributes (4)  ·  Infections (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  RNA Virus Infections (4)  ·  Virus Diseases (4)  ·  Arenaviridae Infections (2)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Lung Diseases (1)  ·  Nidovirales Infections (1)  ·  Pneumonia (1)  ·  Pneumonia, Viral (1)  ·  Respiratory Tract Diseases (1)

Interventions

Standard of Care (2)  ·  Dexamethasone (1)  ·  Ribavirin (1)  ·  baricitinib (1)  ·  favipiravir (1)

Sponsors

Arisan Therapeutics, Inc. (1)  ·  Irrua Specialist Teaching Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Oslo University Hospital (1)

Countries

Nigeria (2)  ·  United States (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Italy (1)  ·  Liberia (1)  ·  Luxembourg (1)  ·  Norway (1)  ·  Portugal (1)

Top investigators

Domique Costagliola, PhD (1)  ·  John Beigel, MD (1)  ·  Jose R Arribas, MD PhD (1)  ·  Ken McCormack, PhD (1)  ·  Richard Davey, MD (1)

Results publications

PMID 28522352, PMID 34473343, PMID 36627655